Prognostic impact of adjuvant chemotherapy treatment intensity for ovarian cancer.

This study investigated the impact of the timing and duration of first-line chemotherapy on outcomes for patients with epithelial ovarian cancer (EOC). Researchers analyzed electronic medical records from 505 women who received platinum/taxane adjuvant regimens, focusing on 222 women with stage IIIC/IV disease for survival analyses. The study compared progression-free survival (PFS), which is the time without disease progression, and overall survival (OS), across groups who completed chemotherapy on time (105 days), finished early, or experienced delays. Statistical methods like Kaplan-Meier functions were used to estimate survival. Key findings showed that on-time chemotherapy completion correlated with increased survival and higher complete response rates. Specifically, patients completing treatment on schedule had a median overall survival of 43.1 months, similar to those with delays less than one month (44.5 months). However, women with delays longer than one month had a significantly reduced median survival of 18.1 months. Shortened chemotherapy regimens also led to decreased survival, with a median of 35.0 months. Progression-free survival showed a similar trend, significantly decreasing after six weeks of delay. The study highlights the critical importance of maintaining the prescribed chemotherapy schedule to improve patient outcomes, suggesting that strategies like dose reduction or growth factor support might be better than treatment delays. However, the study was retrospective, had a limited number of non-serous cancer types for analysis, and did not control for all unmodifiable risk factors like age, BMI, and other health conditions.